3 GLP-1 receptor signaling and GLP-1RA in metabolic disorders The global prevalence of metabolic dysfunction, encompassing obesity and T2DM, has reached pandemic proportions (Chew et al., 2023), characterized by a complex interplay of insulin resistance (Barber et al., 2021), low-grade systemic inflammation (Rohm et al., 2022), and organelle dysfunction (Arruda and Hotamisligil, 2015
Have realistic expectations
That clinician decides whether treatment is appropriate
Clinical trials have shown that 2000-3000mg daily is effective at reducing the rate of cognitive decline measured by a range of parameters
Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for myalgic Encephalomyelitis/Chronic fatigue syndrome